See more : Clean Energy Fuels Corp. (CLNE) Income Statement Analysis – Financial Results
Complete financial analysis of Frequency Therapeutics, Inc. (FREQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Frequency Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Chinese Strategic Holdings Limited (8089.HK) Income Statement Analysis – Financial Results
- Cathay Financial Holding Co., Ltd. (2882.TW) Income Statement Analysis – Financial Results
- Coventry Group Ltd (CVTYF) Income Statement Analysis – Financial Results
- Thermic Sciences International (ENDO) Income Statement Analysis – Financial Results
- SSH Group Limited (SSH.AX) Income Statement Analysis – Financial Results
Frequency Therapeutics, Inc. (FREQ)
About Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 49.42M | 60.92M | 37.42M | 18.78M | 11.88M | 11.97M |
| General & Administrative | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Other Expenses | 1.06M | -266.00K | 0.00 | 16.00M | 0.00 | 0.00 |
| Operating Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Cost & Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 1.33M | 397.00K | 994.00K | 1.78M | 0.00 | -174.00K |
| Interest Expense | 961.00K | 764.00K | 0.00 | 1.78M | 106.00K | 174.00K |
| Depreciation & Amortization | 2.38M | 2.91M | -80.00K | -145.00K | 654.00K | 531.00K |
| EBITDA | -80.62M | -81.13M | -27.55M | -20.68M | -18.29M | -12.02M |
| EBITDA Ratio | 0.00% | -576.66% | -74.71% | -71.92% | 0.00% | 0.00% |
| Operating Income | -83.00M | -84.03M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | -597.32% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | -640.00K | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.58M | -84.67M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | -601.87% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | -2.00K | 15.00K | 35.00K | -2.74M | -118.00K | 3.93M |
| Net Income | -81.58M | -84.69M | -26.51M | -16.00M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | -601.98% | -71.68% | -55.29% | 0.00% | 0.00% |
| EPS | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| EPS Diluted | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| Weighted Avg Shares Out | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
| Weighted Avg Shares Out (Dil) | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth
FREQ Stock: 80.54% Plummet Explanation
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
Source: https://incomestatements.info
Category: Stock Reports